Holen Sie sich die Stockscreener-App
20.32
3.71%
-0.7292
Schlusskurs vom Vortag:
$21.05
Offen:
$20.93
24-Stunden-Volumen:
91,908
Relative Volume:
0.10
Marktkapitalisierung:
$81.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-27.84
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
-12.29%
1M Leistung:
+170.99%
6M Leistung:
+107.88%
1J Leistung:
+123.85%
1-Tages-Spanne:
$19.40
$21.50
1-Wochen-Bereich:
$18.67
$30.30
52-Wochen-Spanne:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
20.37 | 111.64M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.73 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.83 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.57 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.02 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.83 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
What drives MiNK Therapeutics Inc. stock priceUnprecedented profits - jammulinksnews.com
What analysts say about MiNK Therapeutics Inc. stockBreakneck growth rates - jammulinksnews.com
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Is MiNK Therapeutics Inc. a good long term investmentFree Investment Timing Strategies - jammulinksnews.com
MiNK Therapeutics Inc. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
How MiNK Therapeutics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
MiNK Therapeutics (NASDAQ:INKT) Upgraded at B. Riley - Defense World
MiNK Therapeutics Announces Clinical Trial Success - MSN
MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily
MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
MiNK Therapeutics (NASDAQ:INKT) Downgraded to “Neutral” Rating by HC Wainwright - Defense World
Mink Therapeutics stock tumbles on $50 million stock offering - Investing.com
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
What makes MiNK Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
Why MiNK Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright - Investing.com Canada
MiNK Therapeutics Plummets 29%—What’s Driving the Sell-Off? - AInvest
MiNK Therapeutics Plummets 28.59% — What’s Driving the Sell-Off? - AInvest
Mink Therapeutics stock tumbles on $50 million stock offering By Investing.com - Investing.com Nigeria
MiNK Therapeutics publishes research on CAR-iNKT cell therapy By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities - Investing.com Canada
MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors - Nasdaq
MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - TradingView
Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan
MiNK Therapeutics tumbles after $50 mln stock offering filing - TradingView
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - TipRanks
MiNK Therapeutics Plunges 24.87% After William Blair Downgrade - AInvest
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
Promising Medical Stocks To Add to Your Watchlist – July 13th - Defense World
MiNK Therapeutics Plummets to 449th in Trading Volume Amid 91.42% Decline - AInvest
MiNK Therapeutics Shares Skyrocket After Landmark Cancer Remission Result - MSN
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.11%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):